Difference between revisions of "LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5 (Q9853)"
Jump to navigation
Jump to search
(Created claim: Volume (P103): 33, #quickstatements; #temporary_batch_1590009084631) |
(Created claim: title (P93): A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors, #quickstatements; #temporary_batch_1590010982689) |
||
| Property / title | |||
| + | A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors (English) | ||
| Property / title: A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors (English) / rank | |||
| + | Normal rank | ||
Revision as of 22:04, 20 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
LoConte NK, et al. Invest. N. Drugs (2015) cited as Ref 590 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
LoConte NK
0 references
2015
0 references
Invest. N. Drugs
0 references
33
0 references
A multicenter phase 1 study of gamma -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors (English)
0 references
